Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Atara Biotherapeutics stock in Canada | $13.56

Own Atara Biotherapeutics shares in just a few minutes.

Atara Biotherapeutics, Inc
NASDAQ: ATRA - USD
BIOTECHNOLOGY
$12.99
+$0.24 (+1.88%)

Atara Biotherapeutics is a biotechnology business based in the US. Atara Biotherapeutics stocks (ATRA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $14 – an increase of 2.49% over the previous week. Atara Biotherapeutics employs 480 staff and has a trailing 12-month revenue of around $3.6 million.

How to buy Atara Biotherapeutics stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ATRA in this case.
  5. Research Atara Biotherapeutics stocks. The platform should provide the latest information available.
  6. Buy your Atara Biotherapeutics stocks. It's that simple.

How has Coronavirus impacted Atara Biotherapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Atara Biotherapeutics's stock price has had significant positive movement.

Its last market close was $13.56, which is 2.73% up on its pre-crash value of $13.19 and 200.00% up on the lowest point reached during the March crash when the stocks fell as low as $4.52.

If you had bought $1,000 worth of Atara Biotherapeutics stocks at the start of February 2020, those stocks would have been worth $572.18 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $983.37.

Atara Biotherapeutics stock price

Use our graph to track the performance of ATRA stocks over time.

Atara Biotherapeutics stocks at a glance

Information last updated 2021-07-31.
Latest market close$13.56
52-week range$11.33 - $26.1
50-day moving average $14.425
200-day moving average $15.464
Wall St. target price$35.29
Dividend yield N/A (0%)
Earnings per share (TTM) $-6.071

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Atara Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Atara Biotherapeutics price performance over time

Historical closes compared with the last close of $13.56

1 month (2021-07-02) -14.82%
3 months (2021-04-30) -3.56%

Atara Biotherapeutics financials

Revenue TTM USD$3.6 million
Gross profit TTM USD$0
Return on assets TTM -47.13%
Return on equity TTM -95.56%
Profit margin 0%
Book value $4.746
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

How to short and sell Atara Biotherapeutics stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ATRA.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 12.1 million Atara Biotherapeutics stocks held short by investors – that's known as Atara Biotherapeutics's "short interest". This figure is 3.7% up from 11.7 million last month.

There are a few different ways that this level of interest in shorting Atara Biotherapeutics stocks can be evaluated.

Atara Biotherapeutics's "short interest ratio" (SIR)

Atara Biotherapeutics's "short interest ratio" (SIR) is the quantity of Atara Biotherapeutics stocks currently shorted divided by the average quantity of Atara Biotherapeutics stocks traded daily (recently around 916927.23823976). Atara Biotherapeutics's SIR currently stands at 13.18. In other words for every 100,000 Atara Biotherapeutics stocks traded daily on the market, roughly 13180 stocks are currently held short.

However Atara Biotherapeutics's short interest can also be evaluated against the total number of Atara Biotherapeutics stocks, or, against the total number of tradable Atara Biotherapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atara Biotherapeutics's short interest could be expressed as 0.14% of the outstanding stocks (for every 100,000 Atara Biotherapeutics stocks in existence, roughly 140 stocks are currently held short) or 0.1979% of the tradable stocks (for every 100,000 tradable Atara Biotherapeutics stocks, roughly 198 stocks are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the stock price and a discouraging interest in betting against Atara Biotherapeutics.

Find out more about how you can short Atara Biotherapeutics stock.

Atara Biotherapeutics stock dividends

We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Atara Biotherapeutics stock price volatility

Over the last 12 months, Atara Biotherapeutics's stocks have ranged in value from as little as $11.33 up to $26.1. A popular way to gauge a stock's volatility is its "beta".

ATRA.US volatility(beta: 2.44)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 2.4363. This would suggest that Atara Biotherapeutics's stocks are significantly more volatile than the average for this exchange and represent a higher risk.

Atara Biotherapeutics overview

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Stocks similar to Atara Biotherapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site